Video

Dr. Marc Bjurlin on Predictive Models for Prostate Cancer Risk

Marc Bjurlin, DO, clinical assistant professor, department of urology, New York University (NYU) Langone Medical Center, discusses predictive models for prostate cancer risk.

One of the controversies in prostate cancer is which men require a prostate biopsy and of those men, which have a risk of having clinically significant cancer that warrants treatment, explained Bjurlin.

Bjurlin’s team built predictive models that can determine the likelihood of having cancer and of having high-risk disease. They did this using several different clinical parameters, including a multiparametric MRI of the prostate. This is used in conjunction with PSA and family history to determine if patients should get a biopsy and their likelihood of having clinically significant prostate cancer.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center